Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)
Latest Information Update: 13 Sep 2021
At a glance
- Drugs Selinexor (Primary) ; Talazoparib (Primary)
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms START
- 13 Sep 2021 New trial record